Aquestive Therapeutics, Inc. (NASDAQ:AQST) Given Consensus Rating of “Buy” by Analysts

Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) have been assigned a consensus rating of “Buy” from the seven analysts that are covering the stock, MarketBeat reports. Six equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $11.00.

Several research analysts recently issued reports on AQST shares. Cantor Fitzgerald began coverage on shares of Aquestive Therapeutics in a research note on Tuesday, December 17th. They set an “overweight” rating and a $17.00 target price on the stock. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Aquestive Therapeutics in a research report on Friday, December 20th.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Verition Fund Management LLC bought a new stake in shares of Aquestive Therapeutics during the third quarter worth about $995,000. State Street Corp boosted its stake in Aquestive Therapeutics by 52.1% during the 3rd quarter. State Street Corp now owns 1,496,739 shares of the company’s stock valued at $7,454,000 after purchasing an additional 512,682 shares during the last quarter. Harvey Capital Management Inc. boosted its stake in Aquestive Therapeutics by 1,419.3% during the 4th quarter. Harvey Capital Management Inc. now owns 267,390 shares of the company’s stock valued at $952,000 after purchasing an additional 249,790 shares during the last quarter. Wellington Management Group LLP bought a new stake in Aquestive Therapeutics during the 3rd quarter worth approximately $922,000. Finally, Chartwell Investment Partners LLC purchased a new stake in shares of Aquestive Therapeutics in the third quarter worth approximately $535,000. Institutional investors and hedge funds own 32.45% of the company’s stock.

Aquestive Therapeutics Price Performance

Shares of Aquestive Therapeutics stock opened at $2.79 on Thursday. The stock’s 50-day moving average is $3.14 and its 200 day moving average is $4.14. Aquestive Therapeutics has a one year low of $2.24 and a one year high of $6.23. The firm has a market cap of $254.39 million, a price-to-earnings ratio of -6.20 and a beta of 2.76.

Aquestive Therapeutics (NASDAQ:AQST) last posted its quarterly earnings results on Wednesday, March 5th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05). The business had revenue of $11.87 million during the quarter, compared to analysts’ expectations of $13.11 million. On average, sell-side analysts expect that Aquestive Therapeutics will post -0.46 EPS for the current fiscal year.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.